Evidence map›Paper›PMID 37023333›Full record

ArticleJournal of medicinal chemistry2023

Lead Optimization of Androgen Receptor-HSP27 Disrupting Agents in Glioblastoma.

Yaxin Li, Cody Orahoske, Fatma Salem, Aidyn Johnson, Christia Tannous, Lucas Devole, Wenjing Zhang, Justin D Lathia, Bingcheng Wang, Bin Su

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yaxin LiDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Arts and Sciences, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Cody OrahoskeDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Arts and Sciences, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Fatma SalemDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Arts and Sciences, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Aidyn JohnsonDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Arts and Sciences, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Christia TannousDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Arts and Sciences, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Lucas DevoleDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Arts and Sciences, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Wenjing ZhangDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Arts and Sciences, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.
Justin D LathiaLerner Research Institute, Cleveland Clinic, and Case Comprehensive Cancer Center, Cleveland, Ohio 44195, United States.
Bingcheng WangRammelkamp Center for Research and Department of Medicine, MetroHealth Campus, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44109, United States.
Bin SuDepartment of Chemistry, Center for Gene Regulation in Health and Disease, College of Arts and Sciences, Cleveland State University, 2121 Euclid Ave., Cleveland, Ohio 44115, United States.ORCID 0000-0002-0711-441X
Cleveland State University · USCleveland Clinic Lerner College of Medicine · USMetroHealth · US

Funding

Targeting Androgen Receptor-HSP27 Signaling in GlioblastomaR15NS116766 · NINDS · CLEVELAND STATE UNIVERSITY · PI SU, BIN · 2021 to 2025
$891k
A Digital Laser Scanner Biomolecular Imaging System: Amersham Typhoon 5S10OD025252 · OD · CLEVELAND STATE UNIVERSITY · PI LI, BIBO · 2018 to 2018
$163k
NIH HHS S10 OD025252NINDS NIH HHS R15 NS116766
6 · The paper itself

Abstract

Glioblastoma (GBM) is the most common malignant brain tumor with poor prognosis under the current standard treatment. It is critical to develop new approaches to selectively battle the disease. GBM sex differences suggest that an androgen receptor (AR) is a potential therapeutic target to treat AR-overexpressed GBM. Heat shock 27 kDa protein (HSP27) is a well-documented chaperone protein that stabilizes AR. Inhibition of HSP27 leads to AR degradation, indicating that HSP27 inhibitors could suppress AR activity in GBM. We have identified a lead HSP27 inhibitor that could induce AR degradation. Lead optimization resulted with two new derivatives (compounds

Indexed as

GlioblastomaHeat-Shock ProteinsCell Line, TumorFemaleHSP27 Heat-Shock ProteinsHumansMaleReceptors, AndrogenHeat-Shock ProteinsHSP27 Heat-Shock ProteinsReceptors, Androgen

Identifiers

PMID37023333
PMCPMC11068032
OpenAlexW4362661577

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.